PL3993807T3 - SPOSÓB STABILIZOWANIA pH WODNEJ KOMPOZYCJI ZAWIERAJĄCEJ LEK - Google Patents
SPOSÓB STABILIZOWANIA pH WODNEJ KOMPOZYCJI ZAWIERAJĄCEJ LEKInfo
- Publication number
- PL3993807T3 PL3993807T3 PL20734428.4T PL20734428T PL3993807T3 PL 3993807 T3 PL3993807 T3 PL 3993807T3 PL 20734428 T PL20734428 T PL 20734428T PL 3993807 T3 PL3993807 T3 PL 3993807T3
- Authority
- PL
- Poland
- Prior art keywords
- stabilizing
- drug
- aqueous composition
- aqueous
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183719 | 2019-07-01 | ||
| EP20174202 | 2020-05-12 | ||
| PCT/EP2020/068398 WO2021001366A1 (en) | 2019-07-01 | 2020-06-30 | Method for stabilizing the ph of an aqueous composition comprising a drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3993807T3 true PL3993807T3 (pl) | 2026-05-18 |
Family
ID=71130991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20734428.4T PL3993807T3 (pl) | 2019-07-01 | 2020-06-30 | SPOSÓB STABILIZOWANIA pH WODNEJ KOMPOZYCJI ZAWIERAJĄCEJ LEK |
Country Status (24)
| Country | Link |
|---|---|
| US (12) | US12097209B2 (pl) |
| EP (2) | EP3993807B1 (pl) |
| JP (2) | JP7716996B2 (pl) |
| KR (1) | KR20220031909A (pl) |
| CN (1) | CN114040766A (pl) |
| AU (2) | AU2020298754B2 (pl) |
| BR (1) | BR112021026564A2 (pl) |
| CA (1) | CA3142247A1 (pl) |
| CL (1) | CL2021003532A1 (pl) |
| CO (1) | CO2021017558A2 (pl) |
| DK (1) | DK3993807T3 (pl) |
| ES (1) | ES3058853T3 (pl) |
| FI (1) | FI3993807T3 (pl) |
| HR (1) | HRP20260033T1 (pl) |
| IL (1) | IL289520A (pl) |
| LT (1) | LT3993807T (pl) |
| MX (2) | MX2021015767A (pl) |
| PH (1) | PH12021553040A1 (pl) |
| PL (1) | PL3993807T3 (pl) |
| RS (1) | RS67617B1 (pl) |
| SI (1) | SI3993807T1 (pl) |
| SM (1) | SMT202600106T1 (pl) |
| WO (1) | WO2021001366A1 (pl) |
| ZA (1) | ZA202109597B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3548091T (pt) | 2016-11-29 | 2022-01-21 | Oculis SA | Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo |
| WO2021001366A1 (en) | 2019-07-01 | 2021-01-07 | Oculis SA | Method for stabilizing the ph of an aqueous composition comprising a drug |
| KR102589130B1 (ko) * | 2021-03-24 | 2023-10-13 | 삼진제약주식회사 | N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물 |
| US11951087B2 (en) * | 2021-07-27 | 2024-04-09 | Lanny Leo Johnson | Eye wash compositions and methods |
| CN118647364A (zh) * | 2022-02-02 | 2024-09-13 | 奥库里斯经营管理有限责任公司 | 多剂量眼用组合物 |
| US20240261220A1 (en) * | 2023-02-06 | 2024-08-08 | Juewen Liu | Aptamer functionalized liposomes for delivery of ocular drug for eye diseases |
| WO2025083031A1 (en) | 2023-10-16 | 2025-04-24 | Oculis Operations Sàrl | Method of treating diabetic macular edema |
| WO2025082585A1 (en) | 2023-10-16 | 2025-04-24 | Oculis Operations Sàrl | Method of treating diabetic macular edema |
| WO2026094048A1 (en) | 2024-10-30 | 2026-05-07 | Able Tx Ltd. | Drug delivery to the posterior eye segment |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US172A (en) | 1837-04-20 | Improvement in the mode of | ||
| US8633A (en) | 1852-01-06 | Improvement in daguerreotype pictures | ||
| JPS60149530A (ja) | 1984-01-13 | 1985-08-07 | Takeda Chem Ind Ltd | 水性製剤 |
| JP2577049B2 (ja) | 1987-06-04 | 1997-01-29 | 三共株式会社 | シクロスポリン製剤 |
| SG45449A1 (en) * | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| EP0709099A3 (en) | 1994-09-28 | 1996-07-24 | Senju Pharma Co | Aqueous suspension for nasal administration containing cyclodextrin |
| TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| WO1998006381A1 (en) | 1996-08-09 | 1998-02-19 | Alcon Laboratories, Inc. | Preservative systems for pharmaceutical compositions containing cyclodextrins |
| EP0931388B1 (en) | 1996-08-29 | 2003-11-05 | Cisco Technology, Inc. | Spatio-temporal processing for communication |
| EP0938896A1 (en) * | 1998-01-15 | 1999-09-01 | Novartis AG | Autoclavable pharmaceutical compositions containing a chelating agent |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| CZ20012038A3 (cs) | 1998-12-23 | 2001-09-12 | Idea Ag | Zdokonalený přípravek pro topické, neinvazivní použití in vivo |
| DE19957788A1 (de) | 1999-12-01 | 2001-07-05 | Schott Glas | Tropfflasche |
| DE10036871A1 (de) | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| EP1337237B1 (en) | 2000-11-15 | 2009-03-11 | Mohan A. Chandavarkar | Pharmaceutical preparations comprising corticosteroids and antiinfective agents |
| EP1478404A1 (en) * | 2002-02-22 | 2004-11-24 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| WO2004069280A1 (en) | 2003-02-06 | 2004-08-19 | Cipla Ltd | Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent |
| US20070148192A1 (en) | 2003-02-21 | 2007-06-28 | Laddha Ritu N | Stable ophthalmic composition |
| ES2584183T3 (es) | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| CN1559413A (zh) | 2004-02-26 | 2005-01-05 | 胡秀爱 | 地塞米松磷酸钠冻干粉针及制备方法 |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US6969706B1 (en) | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| CN100584332C (zh) | 2004-12-08 | 2010-01-27 | 胡世兴 | 含有粉防己碱的眼用制剂及其在制备治疗眼科疾病的含有粉防己碱的眼用制剂中的应用 |
| WO2006062875A1 (en) | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2008057360A1 (en) | 2006-11-02 | 2008-05-15 | Riolan Technologies, Inc. | Methods of treating an ocular allergy with low dose dexamethasone |
| JP2010531898A (ja) * | 2007-06-28 | 2010-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 鼻および眼へのコルチコステロイド水溶液送達 |
| ES2493641T3 (es) | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US8524267B2 (en) | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| US20110212142A1 (en) * | 2008-11-17 | 2011-09-01 | Laila Pharmaceuticals Pvt.Ltd. | Curcuminoids and its metabolites for the application in ocular diseases |
| CN101926760A (zh) | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 2-羟丙基-β-环糊精包合地塞米松注射液 |
| US8708781B2 (en) | 2010-12-05 | 2014-04-29 | Ethicon, Inc. | Systems and methods for grinding refractory metals and refractory metal alloys |
| US9034931B2 (en) | 2010-12-28 | 2015-05-19 | Rohto Pharmaceutical Co., Ltd. | Aqueous ophthalmic composition |
| US20140163080A1 (en) | 2011-02-03 | 2014-06-12 | Gnt, Llc | Compositions and Methods for Treatment of Glaucoma |
| AU2013259573B2 (en) | 2012-05-08 | 2018-02-15 | Onyx Therapeutics, Inc. | Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors |
| KR101370411B1 (ko) | 2012-08-24 | 2014-03-06 | 린나이코리아 주식회사 | 스팀 컨벡션 오븐 |
| PL2887923T3 (pl) | 2012-08-24 | 2023-08-14 | Sun Pharmaceutical Industries Limited | Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu |
| KR101475776B1 (ko) | 2012-08-24 | 2014-12-24 | 영진약품공업 주식회사 | 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물 |
| DK3043777T3 (da) * | 2013-09-10 | 2020-07-20 | Fresh Cut Dev Llc | Sublingual buprenorphinspray |
| BR112017002356A2 (pt) * | 2014-08-08 | 2017-11-28 | Shanghai Hightide Biopharmaceutical Ltd | composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos |
| AU2016272700A1 (en) * | 2015-05-29 | 2017-12-14 | Oculis ehf. | Formation of cyclosporin A/cyclodextrin nanoparticles |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| WO2017007957A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Reduced sodium poloxamer-188 formulations and methods for use |
| AR106691A1 (es) | 2015-11-13 | 2018-02-07 | Ohr Pharmaceutical Inc | Formulaciones oftálmicas de escualamina |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| PT3548091T (pt) | 2016-11-29 | 2022-01-21 | Oculis SA | Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo |
| WO2019043169A1 (en) | 2017-09-01 | 2019-03-07 | Murray & Poole Enterprises, Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS |
| US20190105264A1 (en) | 2017-10-06 | 2019-04-11 | Aciont Inc. | Non-invasive ocular drug delivery devices |
| JP7324210B2 (ja) | 2018-01-31 | 2023-08-09 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | トファシチニブを含む局所製剤 |
| JP2022516099A (ja) | 2018-12-27 | 2022-02-24 | サーフィス オフサルミクス，インコーポレイテッド | 眼科用医薬組成物及び癌表面疾患の処置方法 |
| WO2021001366A1 (en) | 2019-07-01 | 2021-01-07 | Oculis SA | Method for stabilizing the ph of an aqueous composition comprising a drug |
| EA202290086A1 (ru) | 2020-05-12 | 2022-03-18 | Окюлис Са | СПОСОБ СТАБИЛИЗАЦИИ рН ВОДНОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ЛЕКАРСТВЕННОЕ СРЕДСТВО |
| CN118647364A (zh) | 2022-02-02 | 2024-09-13 | 奥库里斯经营管理有限责任公司 | 多剂量眼用组合物 |
| CN115837027A (zh) | 2022-11-15 | 2023-03-24 | 中国药科大学 | 一种眼用地塞米松药物组合物 |
| WO2025083031A1 (en) | 2023-10-16 | 2025-04-24 | Oculis Operations Sàrl | Method of treating diabetic macular edema |
-
2020
- 2020-06-30 WO PCT/EP2020/068398 patent/WO2021001366A1/en not_active Ceased
- 2020-06-30 EP EP20734428.4A patent/EP3993807B1/en active Active
- 2020-06-30 ES ES20734428T patent/ES3058853T3/es active Active
- 2020-06-30 BR BR112021026564A patent/BR112021026564A2/pt unknown
- 2020-06-30 KR KR1020227003115A patent/KR20220031909A/ko not_active Ceased
- 2020-06-30 FI FIEP20734428.4T patent/FI3993807T3/fi active
- 2020-06-30 PL PL20734428.4T patent/PL3993807T3/pl unknown
- 2020-06-30 SM SM20260106T patent/SMT202600106T1/it unknown
- 2020-06-30 AU AU2020298754A patent/AU2020298754B2/en active Active
- 2020-06-30 SI SI202030722T patent/SI3993807T1/sl unknown
- 2020-06-30 CN CN202080047930.6A patent/CN114040766A/zh active Pending
- 2020-06-30 HR HRP20260033TT patent/HRP20260033T1/hr unknown
- 2020-06-30 MX MX2021015767A patent/MX2021015767A/es unknown
- 2020-06-30 CA CA3142247A patent/CA3142247A1/en active Pending
- 2020-06-30 PH PH1/2021/553040A patent/PH12021553040A1/en unknown
- 2020-06-30 US US17/624,311 patent/US12097209B2/en active Active
- 2020-06-30 RS RS20260019A patent/RS67617B1/sr unknown
- 2020-06-30 LT LTEPPCT/EP2020/068398T patent/LT3993807T/lt unknown
- 2020-06-30 EP EP25216015.5A patent/EP4670738A3/en active Pending
- 2020-06-30 DK DK20734428.4T patent/DK3993807T3/da active
- 2020-06-30 JP JP2021578118A patent/JP7716996B2/ja active Active
-
2021
- 2021-11-25 ZA ZA2021/09597A patent/ZA202109597B/en unknown
- 2021-12-15 MX MX2026000961A patent/MX2026000961A/es unknown
- 2021-12-21 CO CONC2021/0017558A patent/CO2021017558A2/es unknown
- 2021-12-28 CL CL2021003532A patent/CL2021003532A1/es unknown
- 2021-12-30 IL IL289520A patent/IL289520A/en unknown
-
2023
- 2023-10-26 US US18/383,991 patent/US12090160B2/en active Active
- 2023-10-26 US US18/384,000 patent/US12090162B2/en active Active
- 2023-10-26 US US18/383,993 patent/US12090161B2/en active Active
- 2023-10-26 US US18/383,999 patent/US20240058361A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/893,790 patent/US12403147B2/en active Active
- 2024-09-23 US US18/893,810 patent/US12403148B2/en active Active
- 2024-09-23 US US18/893,806 patent/US12397002B2/en active Active
- 2024-09-23 US US18/893,805 patent/US12383565B2/en active Active
- 2024-09-23 US US18/893,796 patent/US12397000B2/en active Active
- 2024-09-23 US US18/893,798 patent/US12397001B2/en active Active
-
2025
- 2025-03-27 JP JP2025053165A patent/JP2025098194A/ja active Pending
- 2025-08-22 AU AU2025220806A patent/AU2025220806A1/en active Pending
- 2025-08-28 US US19/313,674 patent/US20250387411A1/en active Pending